HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,292,189 | +2.8% | 164,717 | -2.9% | 0.03% | +7.4% |
| Q2 2023 | $6,120,863 | -9.3% | 169,694 | -3.9% | 0.03% | -6.9% |
| Q1 2023 | $6,747,065 | -33.5% | 176,671 | -0.9% | 0.03% | -34.1% |
| Q4 2022 | $10,140,377 | +42.2% | 178,214 | -1.2% | 0.04% | +33.3% |
| Q3 2022 | $7,132,000 | -10.8% | 180,377 | -0.7% | 0.03% | -2.9% |
| Q2 2022 | $7,996,000 | +8.5% | 181,724 | -1.6% | 0.03% | +25.9% |
| Q1 2022 | $7,367,000 | -0.6% | 184,728 | +0.2% | 0.03% | +3.8% |
| Q4 2021 | $7,413,000 | -1.1% | 184,356 | +0.0% | 0.03% | -7.1% |
| Q3 2021 | $7,497,000 | -5.3% | 184,296 | +5.7% | 0.03% | -3.4% |
| Q2 2021 | $7,918,000 | +14.4% | 174,366 | +5.1% | 0.03% | +11.5% |
| Q1 2021 | $6,919,000 | -2.2% | 165,972 | +0.2% | 0.03% | -7.1% |
| Q4 2020 | $7,074,000 | – | 165,634 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |